Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Context Therapeutics Inc. | Onapristone (ONA-XR) | Ovarian cancer | Phase 2 | Trial Discontinued | oral | Oncology |
| Context Therapeutics Inc. | Onapristone (ONA-XR) and Anastrozole - (OATH) | Endometrial Cancer | Phase 2 | Trial Discontinued | Oral | Oncology |
| Context Therapeutics Inc. | Onapristone (ONA-XR) and Fulvestrant (The SMILE Study) | Breast Cancer - 2nd-line | Phase 2 | Trial Discontinued | Oral and intramuscular | Oncology |
| Context Therapeutics Inc. | FEMARA (Letrozole) IBRANCE (Palbociclib) and Onapristone (ONA-XR) | Breast cancer - first line | Phase 2 | Trial Discontinued | Oral | Oncology |
| Contineum Therapeutics Inc. | PIPE-307 - (VISTA) | Relapse-remitting multiple sclerosis (RRMS) | Phase 2 | Data Released | Oral | Neurology |
| ContraFect Corporation | Exebacase - (DISRUPT) | Serious infections caused by Staph aureus including MRSA | Phase 3 | Intravenous | Antibiotic | |
| Corbus Pharmaceuticals Holdings Inc. | Lenabasum (Resunab) | Systemic lupus erythematosus (SLE) | Phase 2 | Trial Discontinued | Oral | Immunology |
| Corbus Pharmaceuticals Holdings Inc. | Lenabasum (Resunab) | Cystic Fibrosis | Phase 2b | Trial Discontinued | Oral | Respiratory |
